Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes.
Journal
Clinical lymphoma, myeloma & leukemia
Journal Volume
24
Journal Issue
9
Pages
e320 - e328
ISSN
2152-2669
Date Issued
2024-09
Author(s)
Tan, Daryl
Chan, Jason Yongsheng
Wudhikarn, Kitsada
Wong, Raymond Siu Ming
Poon, Limei
Norasetthada, Lalita
Tse, Eric
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for around 30-60% of all cases. The management of DLBCL in Asia has several unmet needs due to the diversity of the population, the heterogeneity of local clinical guidelines for DLBCL and the wide disparity in resources and healthcare systems across different regions. Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) is widely recognized as the standard first-line treatment for DLBCL; however, alternative regimens are required to improve patient outcomes in challenging subtypes, such as patients with high International Prognostic Index scores, old/frail patients, and patients with double-hit and double-expressor DLBCL or concurrent central nervous system disease. This review article draws from the expertise of practicing hematologists/oncologists in the region, with the aim of integrating data from current scientific evidence to address the unmet needs and unique socioeconomic challenges faced by challenging high risk patient groups in the Asia-Pacific region.
Subjects
Asia Pacific
IPI
Polatuzumab vedotin
diffuse large B-cell lymphoma
first line
Type
review